Do FBT and GNOM hold the same stocks?

By their latest filings, 23% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, FBT or GNOM?

FBT has 25% of its weight in S&P 500 names and GNOM has 21%, so FBT differs more from the index.

Which is cheaper, FBT or GNOM?

FBT charges 0.55% a year and GNOM charges 0.50%, so GNOM is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Thematic ETFs

FBT vs GNOM: Holdings Overlap & Returns

Share on X Download as PDF

Over the year to Nov 4, 2026, FBT returned +47.0% to GNOM's +66.6%; 23% of their weight is in the same names.

askIQ about this page

askIQ about FBT and GNOM

Net assets: $3.1bn on Nov 3, 2026 for First Trust NYSE Arca Biotechnology Index Fund, and $104m on Oct 12, 2026 for Global X Genomics & Biotechnology ETF.

FBT on its own →GNOM on its own →

At a glance

24.8%

FBT in the S&P 500

21.0%

GNOM in the S&P 500

+47.0%

FBT total return, 1 year

+66.6%

GNOM total return, 1 year

FBT · 1 year to Nov 4, 2026 75% of its weight is outside the S&P 500

25% of FBT's weight is in S&P 500 companies and 75% is outside the index. Holdings as of Nov 3, 2026.

GNOM · 1 year to Nov 4, 2026 79% of its weight is outside the S&P 500

21% of GNOM's weight is in S&P 500 companies and 79% is outside the index. Holdings as of Aug 31, 2026.

Pair scorecard

GNOM costs 0.05 points a year less; their one-year returns differ by 19.6 points; FBT is far larger, $2.9bn against $104m.

FBT vs GNOM: Holdings Overlap & Returns
Measure	FBT	GNOM
Return
Measure	FBT	GNOM
Total return, 1 year	+47.0%	+66.6%
Drawdown
Measure	FBT	GNOM
Below its all-time high		36.2%, high on Feb 8, 2021
Benchmark
Measure	FBT	GNOM
What it tracks	Biotech	Genomics and gene editing
Cost and size
Measure	FBT	GNOM
Expense ratio	0.55%	0.50%
Net assets, as of Oct 12, 2026	$2.9bn	$104m
Holdings
Measure	FBT	GNOM
Holdings in common	23%

Method

Risk and return

Apr 18, 2019 to Oct 30, 2026 · 393 weekly returns

FBT GNOM

Return

Total return edge FBT +108.2% +25.4%

Annualized edge FBT +10.2% +3.0%

Price return edge FBT +104.0% +23.4%

Risk

Volatility edge FBT 21.9% 32.9%

Max drawdown edge FBT −29.0% −73.5%

Risk-adjusted

Sharpe edge FBT 0.42 0.17

Sortino edge FBT 0.63 0.25

Calmar edge FBT 0.35 0.04

Reading

From Apr 2019 to Oct 2026, FBT returned more: +108.2% to +25.4%. FBT swung less: 21.9% to 32.9%. FBT fell less at its worst: −29.0% to −73.5%.

Full scorecard

9 measures, with how each is measured Open ↓

Risk and return: FBT vs GNOM: Holdings Overlap & Returns
Measure	FBT	GNOM	Edge	How it is measured
Return
Total return	+108.2%	+25.4%	FBT	Price change plus distributions, reinvested.
Annualized	+10.2%	+3.0%	FBT	Total return as a yearly rate.
Price return	+104.0%	+23.4%	FBT	Price change alone, distributions left out.
Risk
Volatility	21.9%	32.9%	FBT	Spread of weekly returns, annualized. Lower is steadier.
Downside deviation	14.7%	22.3%	FBT	Like volatility, counting only weeks below the Treasury bill rate.
Max drawdown	−29.0%	−73.5%	FBT	Deepest fall from a high to the low after it.
Risk-adjusted
Sharpe	0.42	0.17	FBT	Return above Treasury bills per unit of volatility.
Sortino	0.63	0.25	FBT	Return above Treasury bills per unit of downside deviation.
Calmar	0.35	0.04	FBT	Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 393 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

23%

By the books each fund has filed, FBT and GNOM hold 23% of their money in the same securities at the same weight. Holdings dated Aug 31, 2026 and Nov 3, 2026.

50%

0 half 100%

half

23% in common

Positions both hold · largest shared weight first FBT GNOM

Vertex Pharmaceuticals Incorporated 3.34% 3.70%

BioMarin Pharmaceutical Inc. 3.26% 3.58%

Bio-Techne Corporation 3.22% 3.67%

Natera, Inc. 3.11% 4.61%

BioNTech SE (ADR) 2.88% 2.78%

Illumina, Inc. 2.75% 4.87%

Veracyte, Inc. 3.57% 2.61%

Gilead Sciences, Inc. 3.56% 1.64%

Bruker Corporation 3.08% 0.33%

Only in one fund ↓

Only in FBT

Genmab A/S (ADR) 4.81%

Regeneron Pharmaceuticals, Inc. 4.18%

Exelixis, Inc. 3.88%

Halozyme Therapeutics, Inc. 3.74%

Neurocrine Biosciences, Inc. 3.71%

Alkermes Plc 3.61%

Amgen Inc. 3.57%

Biogen Inc. 3.54%

Only in GNOM

MODERNA, INC. 7.50%

Twist Bioscience Corporation 6.34%

10x Genomics, Inc. 5.48%

GUARDANT HEALTH, INC. 5.28%

Genscript Biotech Corp 3.81%

ARROWHEAD PHARMACEUTICALS, INC. 3.31%

Qiagen N.V. 3.22%

Praxis Precision Medicines, Inc. 3.09%

Check overlap with more funds →

Window by window

Window by window: FBT vs GNOM: Holdings Overlap & Returns
	Total return
Window	FBT	GNOM
3 months	+12.2%	+24.5%
6 months	+30.5%	+49.4%
1 year	+47.0%	+66.6%
3 years	+100.5%	+81.6%
Since launchNot the same days: FBT Jun 2006 · GNOM Apr 2019	+1,349.5%	+16.0%

Open this comparison in the app →

Side by side

FBT First Trust NYSE Arca Biotechnology Index Fund · Holds 30 stocks in biotech, 25% of its weight in S&P 500 companies GNOM Global X Genomics & Biotechnology ETF · Holds 50 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies

Issuer First Trust Global X

Theme Biotech Genomics and gene editing

In the S&P 500 24.8% 21.0%

Active share vs the S&P 500 99.1% 97.6%

In the Nasdaq-100 16.9% 5.3%

Holdings 30 50

Top ten, share of the fund 38.2% 48.8%

Expense ratio 0.55% 0.50%

Fee for the differing part 0.55% 0.51%

Total return, 1 year +47.0% +66.6%

vs its benchmark not measured not measured

Below its high −0.3% −36.2%

Net assets, FBT as of Nov 3, 2026 and GNOM as of Oct 12, 2026 $3.1bn $104m

As of Nov 4, 2026. Source: ETFIQ.

23% of the two portfolios are the same securities at the same weight.

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

About each fund

FBT

By weight, 25% of FBT's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 38% of the fund across 30 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +47.0% with distributions reinvested.

GNOM

By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 49% of the fund across 50 positions, as filed for Aug 31, 2026. Over the year to Nov 4, 2026 the fund returned +66.6% with distributions reinvested. It sits 36.2% below its all-time high of Feb 8, 2021.

Questions people ask

Do FBT and GNOM hold the same stocks?: By their latest filings, 23% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, FBT or GNOM?: FBT has 25% of its weight in S&P 500 names and GNOM has 21%, so FBT differs more from the index.
Which is cheaper, FBT or GNOM?: FBT charges 0.55% a year and GNOM charges 0.50%, so GNOM is cheaper. Fees come from each fund's prospectus.

Other comparisons

FBT vs GNMX FBT vs IDNA FBT vs ARKG FBT vs PBPH GNOM vs IBB GNOM vs PBPH GNOM vs XBI GNOM vs PBE

Where to next

All thematic ETFs ranked by the S&P 500 Difference Score →How the scores are computed →FBT on its own →GNOM on its own →FBT dividend history →FBT holdings →GNOM dividend history →GNOM holdings →Method →Standards and sources →

Sources and dates

FBT filings on SEC EDGAR ↗

FBT prospectus with the expense ratio (SEC) ↗

First Trust page for FBT ↗

GNOM filings on SEC EDGAR ↗

GNOM prospectus with the expense ratio (SEC) ↗

Global X page for GNOM ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, FBT against GNOM, data as of Nov 4, 2026. https://etfiq.com/compare/themes/fbt-vs-gnom

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.